-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyverna says miv-cel meets primary endpoint in stiff person syndrome trial

PUBT·04/21/2026 22:45:16
Listen to the news
Kyverna says miv-cel meets primary endpoint in stiff person syndrome trial
  • Kyverna disclosed positive primary analysis from KYSA-8, registrational Phase 2 trial of miv-cel in stiff person syndrome, with data presented in a late-breaking oral session at AAN Annual Meeting.
  • Single-dose treatment produced rapid, durable clinical improvement in mobility and disability measures, with patients able to stop chronic immunotherapies.
  • Safety profile supported outpatient use, with no severe cytokine release syndrome or serious neurotoxicity reported.
  • Kyverna is preparing a BLA submission for stiff person syndrome, positioning miv-cel as a potential first approved therapy for the indication.
  • Management scheduled an investor call for April 22, 2026 at 7:00 am ET to discuss KYSA-8 results, with updated Phase 2 generalized myasthenia gravis data from KYSA-6 also presented at AAN.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211845PRIMZONEFULLFEED9694178) on April 21, 2026, and is solely responsible for the information contained therein.